Jan. 17, 2006 — The US Food and Drug Administration (FDA) and Novartis Pharmaceutical Corporation have notified healthcare professionals via letter regarding modifications to the white blood cell ...
The risk for moderate neutropenia associated with clozapine therapy is low in patients with treatment-resistant schizophrenia, and the risk for severe neutropenia is minimal, new research showed. None ...
YOKNEAM ILLIT, Israel, Nov. 29, 2023 /PRNewswire/ -- A groundbreaking study conducted by a University of North Carolina (UNC) research team has unveiled compelling evidence supporting the adoption of ...
The FDA gave ANeuroTech positive feedback during a pre-investigational new drug meeting on the phase IIIb clinical program testing their drug ANT-01 as adjunctive therapy for major depression, the ...
A joint FDA advisory committee on Tuesday overwhelming voted to eliminate the risk evaluation and mitigation strategy (REMS) program designed around the risk for severe neutropenia associated with ...
I have taken clozapine successfully for 17 years. One of my biggest fears in life is reduced access to this life-saving medication. Clozapine brought me to full recovery after every other medication I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results